Acute and chronic hepatitis are two types of liver disease. In acute hepatitis, the virus causes inflammation and fibrosis. In chronic hepatitis, the liver can also be damaged by certain drugs such as paracetamol. While acute hepatitis can be fatal, chronic liver disease develops slowly. Symptoms of chronic liver disease may include hepatitis, cirrhosis, and hepatocellular carcinoma.
Get Research Sample PDF with Market Development Insights @ https://www.coherentmarketinsights.com/insight/request-sample/4920
A better prognosis is offered to patients with compensated chronic liver disease. Those with decompensated cirrhosis have a poor prognosis. If the Child-Pugh score is over 12 or the MELD score is higher than 21, then the prognosis is poor. While this disease does not require surgery, treatment for chronic liver disease involves a multidisciplinary approach. The treatment of chronic liver disease includes correcting underlying causes, managing portal hypertension, and specific treatments for each patient’s condition. Below is a brief outline of the treatment of chronic liver disease. Further details can be found in the Statpearls glossary.
Middle East and Turkey chronic liver disease (CLD) therapeutics market is expected to witness significant growth in the near future, owing to presence of major market players (Gilead Sciences, Inc., AbbVie Inc., Sanofi S.A.). Market players are focused on novel product launches and regulatory approvals and adoption of inorganic growth strategies such as acquisitions, collaborations, and partnerships to strengthen their CLD therapeutics portfolio. For instance, in December 2019, IceCure Medical, a company based in Israel, received the U.S. Food and Drug Administration approval for its Cryoblation technology to expand and treat cancerous tumors in liver.
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 260 million infected individuals worldwide as of December 2021.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by financial impact on firms and financial markets. Due to lockdown, many countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to the transportation of drugs. Furthermore, players operating in the Middle East and Turkey chronic liver disease therapeutics market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials for manufacturing drug formulations due to irregularities in transportation facility and distributors facing irregular demand for products from retailers.
Buy Now to Avail Discount @ https://www.coherentmarketinsights.com/promo/buynow/4920
Thus, coronavirus (COVID-19) pandemic is expected to limit growth of the Middle East and Turkey chronic liver disease therapeutics market over the forecast period.
Key players involved in the market are focused on adopting various inorganic growth strategies such as collaborations, partnerships, and agreements, in order to expand their product offerings in the market. For instance, in June 2020, Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for obeticholic acid (OCA) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
Key Takeaways of the Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market:
- Middle East and Turkey chronic liver disease (CLD) therapeutics market is expected to exhibit a CAGR of 5.8% over the forecast period.
- Among disease type, hepatitis segment is expected to hold the largest market share over the forecast period, owing to growing risk and prevalence of hepatitis virus infection in the Middle East and Turkey, which is projected to augment demand for chronic liver diseases therapeutics in the Middle East and Turkey region. For instance, according to the data published in May 2018, by National Center for Biotechnology Information, Department of Gastroenterology, 37,638 patients for hepatitis in Turkey, within which 1,534 (4%) of individuals were found to be infected with hepatitis B. Furthermore, in Turkey, around 3.3 million HBV carriers was estimated in 2018, with 58% of overall HBV prevalence.
- Among drug class, Chemotherapy Drugs segment is expected to hold the largest market share in 2021, owing to increasing launch of chemotherapy products. For instance, in April 2021, Delcath Systems, Inc., a specialty pharmaceutical and medical device company, launched its Delcath Hepatic Delivery System (CHEMOSAT) for the treatment of liver cancer at Hacettepe University Clinic in Ankara, Turkey.
- Key players operating in the Middle East and Turkey chronic liver disease (CLD) therapeutics market include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc, and Pfizer Inc.
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Country
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Technological Evolution
- Regulatory Scenario
- Key Developments
- Collaboration and Acquisition
- Diagnosis Rate/Ratio
- Pipeline Analysis
- PEST Analysis
- Reimbursement Scenario
- Market Dynamics
- Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, Impact of COVID-19 Pandemic
- COVID19 Impact
- Economic Impact
- Demand and Supply Impact Analysis
- Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Disease Type, 2017-2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Hepatitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Alcohol Induced Liver Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Liver Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Fatty Liver Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Introduction
- Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Drug Class, 2017–2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018–2028
- Segment Trends
- Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Targeted therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Immunoglobulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Introduction
- Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Route of Administration, 2017–2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018–2028
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Introduction
- Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Distribution Channel, 2017–2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018–2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2028, (US$ Mn)
- Introduction
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
Email: sales@coherentmarketinsights.com
Phone: U.S.: +1-206-701-6702
U.K.: +44-020-8133-4027
JAPAN: +81-50-5539-1737
INDIA: +91-848-285-0837